BioSpace News Archive

Zoetis Inc . (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, Nov. 5, 2020. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Glenn David will review third quarter 2020 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website

Today as the 6th annual “Limb Girdle Muscular Dystrophy Awareness Day” is celebrated worldwide, LGMD Awareness Foundation, Inc. is proud to announce their formation as a 501(c)(3) non-profit advocacy organization dedicated to globally raising awareness of the rare neuromuscular diseases known as Limb Girdle Muscular Dystrophy (LGMD).

According to Coherent Market Insights, the Latin America oncology device market is estimated to be valued at US$ 31.08 million in 2020 and is expected to exhibit a CAGR of 5.5 % over the forecast period (2020-2027). Key Trends and Analysis of the Latin America Oncology Device Market: Latin America oncology device market is expected to experience significant growth owing to the increase in prevalence of cancer in th

Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specialized in the development of drug candidates for the treatment of aged related diseases, including neuromuscular diseases, today announced a €10 million capital increase through private placement. The capital increase will be

Access Genetics, LLC dba OralDNA® Labs announces that FDA has issued an amended Emergency Use Authorization for the OraRisk® COVID-19 RT-PCR test allowing testing from a saline oral rinse collection.

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer,

Harbour BioMed (HBM), a global, clinical-stage, bio-pharmaceutical company announced today the dosing of the first patient in two separate Phase II clinical trials of Batoclimab (HBM 9161), a fully human anti-FcRn monoclonal antibody (mAb), in mainland China.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population.

Locus Biosciences announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) to co-fund development of LBP-EC01, a CRISPR Cas3-enhanced bacteriophage (crPhage™) product that will target Escherichia coli ( E. coli ) bacteria causing recurrent urinary tract infections

MDA continues to step up fight against ALS during this challenging time, building on its $168 million research commitment